Stock ALEC ALECTOR, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alector, Inc.

Equities

ALEC

US0144421072

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 07:26:00 29/04/2024 pm IST 		5-day change 1st Jan Change
5.305 USD +1.05% Intraday chart for Alector, Inc. +4.41% -32.35%
17/04 Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024. CI
17/04 Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,188 1,199 1,678 763.3 671.4 506 - -
Enterprise Value (EV) 1 834.5 785.6 943.1 50.48 122.5 -42.91 -197 506
P/E ratio -10.1 x -6.18 x -45.9 x -5.7 x -5.12 x -2.45 x -3.4 x -4.23 x
Yield - - - - - - - -
Capitalization / Revenue 56 x 56.8 x 8.1 x 5.71 x 6.92 x 8.12 x 4.35 x 2.43 x
EV / Revenue 39.3 x 37.2 x 4.55 x 0.38 x 1.26 x -0.69 x -1.69 x 2.43 x
EV / EBITDA -7.54 x -4.15 x -30.4 x -0.38 x -0.84 x 0.21 x 1.31 x -5.15 x
EV / FCF -7.28 x - 3.19 x -2.07 x -0.66 x 0.28 x 1.56 x -2.71 x
FCF Yield -13.7% - 31.3% -48.4% -152% 360% 64% -36.9%
Price to Book 6.11 x 4.49 x 5.63 x 3.57 x 4.98 x 4.73 x 4.82 x -
Nbr of stocks (in thousands) 68,924 79,243 81,276 82,702 84,136 96,385 - -
Reference price 2 17.23 15.13 20.65 9.230 7.980 5.250 5.250 5.250
Announcement Date 24/03/20 25/02/21 24/02/22 28/02/23 27/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 21.22 21.1 207.1 133.6 97.06 62.31 116.2 208
EBITDA 1 -110.6 -189.3 -31.03 -132.1 -146 -199.7 -149.9 -98.25
EBIT 1 -114.4 -195.2 -37.36 -137.8 -151.7 -226.6 -170.9 -132.6
Operating Margin -539.16% -925.08% -18.04% -103.16% -156.33% -363.68% -147% -63.77%
Earnings before Tax (EBT) 1 -105.4 -190.2 -36.33 -130.1 -125.2 -199.9 -127.3 -143.4
Net income 1 -105.4 -190.2 -36.33 -133.3 -130.4 -200.9 -129 -143.4
Net margin -496.65% -901.64% -17.54% -99.77% -134.34% -322.37% -110.94% -68.94%
EPS 2 -1.710 -2.450 -0.4500 -1.620 -1.560 -2.141 -1.544 -1.240
Free Cash Flow 1 -114.6 - 295.3 -24.45 -186.5 -154.4 -126 -186.7
FCF margin -539.95% - 142.6% -18.3% -192.19% -247.74% -108.42% -89.79%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 24/03/20 25/02/21 24/02/22 28/02/23 27/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 182.4 13.99 24.47 79.85 14.85 14.44 16.55 56.21 9.109 15.19 15.76 15.76 15.76 15.76 250
EBITDA - - - - - - - - - -46.02 - - - - -
EBIT 1 126.3 -55.73 -44.12 9.475 -47.75 -55.44 -50.12 -3.589 -50.58 -47.45 -52.08 -55 -57.88 -56.78 191.2
Operating Margin 69.25% -398.23% -180.29% 11.87% -321.49% -383.92% -302.83% -6.38% -555.31% -312.4% -330.46% -349.01% -367.23% -360.29% 76.46%
Earnings before Tax (EBT) 1 126.6 -55.61 -43.86 10.92 -45.42 -51.71 -44.96 2.768 -43.22 -39.77 -47.16 -50.38 -53.54 -48.86 196.7
Net income 1 126.6 -55.61 -44.62 9.883 -46.15 -52.43 -45.86 1.375 -44.48 -41.43 -50.14 -53.51 -51.83 -49.24 188.5
Net margin 69.4% -397.37% -182.3% 12.38% -310.72% -363.07% -277.1% 2.45% -488.25% -272.77% -318.16% -339.5% -328.88% -312.45% 75.39%
EPS 2 1.490 -0.6800 -0.5400 0.1200 -0.5600 -0.6300 -0.5500 0.0200 -0.5300 -0.4900 -0.5357 -0.5529 -0.5371 -0.5143 1.930
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 04/11/21 24/02/22 05/05/22 04/08/22 08/11/22 28/02/23 04/05/23 03/08/23 07/11/23 27/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 353 413 735 713 549 549 703 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -115 - 295 -24.4 -187 -154 -126 -187
ROE (net income / shareholders' equity) -217% -82.3% -12.8% -51.8% -74.8% -172% -132% -
ROA (Net income/ Total Assets) - - - - -18.5% - - -
Assets 1 - - - - 704.7 - - -
Book Value Per Share 2 2.820 3.370 3.670 2.590 1.600 1.110 1.090 -
Cash Flow per Share 2 - -2.140 3.710 -0.2500 -2.200 -1.710 -1.850 -
Capex 1 15.3 5.03 3.25 4.12 2.38 6.62 8.17 8.52
Capex / Sales 71.94% 23.85% 1.57% 3.08% 2.45% 10.62% 7.03% 4.1%
Announcement Date 24/03/20 25/02/21 24/02/22 28/02/23 27/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Alector, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
5.25 USD
Average target price
16.22 USD
Spread / Average Target
+208.99%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ALECTOR, INC. Stock Alector, Inc.
-32.35% 506M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.41% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.73% 95.28B
ARGENX SE Stock argenx SE
+2.30% 22.15B
BIONTECH SE Stock BioNTech SE
-16.37% 21.02B
GENMAB A/S Stock Genmab A/S
-8.77% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.58% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.54% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.04% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALEC Stock
  4. Financials Alector, Inc.